The cannabis bull market is back, fueled by widescale legalization efforts, and it’s giving investors a second chance to buy into the fastest growing sector we’ve ever seen.

  • Loosening regulations in the U.S. could bode well for an undiscovered company that has recently seen its revenues jump 7X year on year.1
  • The company’s experienced team is fearless when it comes to tackling the extensive regulatory environment and knowledge it takes to establish a thriving legal cannabis dispensary conglomerate.
  • Rapid expansion is why its revenues are forecast to rocket nearly 4X to $28 million, then 4X again
  • Now it could have its eyes on the biggest cannabis prize of all

 Chuck Schumer has a plan that could make a lot of investors a lot of money.

That’s because, the Senate Majority Leader from New York wants to legalize recreational marijuana nationwide in the U.S.

Chances are, when Schumer gets his way, the move will ignite an investment frenzy of unprecedented scope.  But, along with fabulous opportunities, Schumer’s plan could unleash a torrent of problems for investors, too.  In the coming months, they’ll be inundated with a huge assortment of companies that claim to be rushing into the legal cannabis space.

The majority of those companies will have low-priced shares that carry a promise to soar within days of purchase, a promise they will be wanton to deliver on.

This Is Where Experience Becomes The Critical Determining Factor

That’s why it’s imperative for investors to take a good look now at Quantum1 Cannabis / Quizam (CSE: QQ | OTCQB: QQQFFCSE: QQ | OTCQB: QQQFF).

Quantum1 is a subsidiary of Quizam Media, which has partnered with Microsoft and Oracle to become one of Canada’s top corporate training centers.2 That training included Quizam producing videos in 2018 for Canada’s nascent cannabis industry.

Ultimately, Quizam’s cannabis expertise grew so vast and deep that it was a no brainer for it to expand into the consumer cannabis market itself. And, while its subsidiary Quantum1 Cannabis could be a solid investment, it is their deep experience that’s a prime example of the rigorous standards investors should hold young cannabis companies to.

In other words, the legal recreational and medical cannabis industries have exceedingly high barriers of entry.

As it once was with Quantum1 Cannabis, a strong predictor of success is the ease and speed that new-to-cannabis-industry companies clear the many legal, regulatory, financial, and community barriers that will be placed in front of them.

Because, it’s one thing to tout a cannabis business… it’s another thing to be approved to operate a cannabis business.

Or, as it is with Quantum1 Cannabis / Quizam (CSE: QQ | OTCQB: QQQFFCSE: QQ | OTCQB: QQQFF), to have scaled the regulatory mountain and now be on pace for what could be $28 million in sales in the next fiscal year.

Smart Cannabis Companies Like Quantum1 Are On A Prolonged Winning Streak

Take a common starting date, Dec. 16, 2018, to make things fair, and just look at how legal cannabis companies have fared the last few years:

Trulieve Cannabis (TRUL.CN)… up 537%.3

Cresco Labs (CL.CN)… up 145%.4

Curaleaf Holdings (CURA.CN)… up 243%.5

Aphria Inc. (APHA.TO)… up 236%.6

This happened all while investors were told to avoid cannabis stocks.

And thanks to Chuck Schumer, there will be no avoiding them now

Voter Data Shows Schumer Is Going To Get His Way

Momentum means the legal marijuana mega trend could have massive staying power as U.S. states, hungry for tax revenue, climb aboard.

The people insist.

At least 74% of Americans born after 1981 support legalized cannabis, while 67% of the entire population favors legal weed.7

Nearly seven-in-ten Democrats say marijuana use should be legal, as do 75% of independents who lean toward the Democratic Party.

Republicans are divided, with 45% in favor of legalizing recreational cannabis and 51% opposed.  Still, the share of Republicans saying marijuana should be legal has increased from 39% in 2015.

That means nationwide prohibition is set to be shattered. And an even greater marijuana frenzy than we saw back in 2018 will sweep across North America.

Investing’s New Wild West

Let’s not forget that barely eight years ago no state other than California, which legalized medicinal marijuana in 1996, tolerated any form of the drug – recreational or medical.

Then, at a historically breakneck pace, as nationwide movements go, voters said ”yes” on 28 separate ballot measures that legalized cannabis.

Of them, 18 legalized medical marijuana, and 10 measures legalized adult recreational use. 

The rapid trend picked up more speed last November when voters delivered a unanimous mandate for recreational marijuana use in Arizona, Montana, New Jersey, and South Dakota.

They also approved its use for medicinal purposes in Mississippi and South Dakota.

The Birth Of A Cannabis Mega Market

The New Jersey vote was key, because the action was widely expected to carry a bigger weight than that…  because, as predicted, it forced New York State’s hand.

New York’s Governor Andrew Cuomo signed legal recreational cannabis into law on March 31.

Now the clocking is ticking on Pennsylvania, which already has medical marijuana, but may need to legalize recreational pot in order to keep those tax dollars at home and away from neighboring states.

So, you could assume that it’ll be “when” not “if” in Pennsylvania.

That would create a tri-state market with a combined GDP of about $3.2 trillion…8

In turn that could eclipse California, creating the world’s biggest legal cannabis market.

It also would make the NY-NJ-PA the world’s fifth largest economy.

The Scope Of This Opportunity Is Heart-Pounding

This is a major event, because as Fortune and Business Insider reports the legal marijuana market is booming.

And get this, Fortune and Business Insider noted that legal cannabis is catching up to beer and wine sales.9

The U.S. recreational and medical marijuana markets are on a trajectory to reach up to $45.9 billion in annual sales by 2025, or as much as twice the level of sales projected for this year.

U.S. adult-use and medical cannabis sales in 2021 are expected to reach $22 billion-$26.4 billion.

If these projections materialize, the value of marijuana sales will grow to two times that of firearms and ammunition, and three times that of McDonald’s sales revenue in the U.S.10

But, all in all, 2020 will likely go down as one of legal cannabis’ most important years.

“Many marijuana businesses were declared essential during the pandemic, and more states legalized cannabis markets. 2021 will see more states join in, and their programs are getting started faster than we’ve previously seen,” said Marijuana Business Factbook Editor Jenel Stelton-Holtmeier.

“There is no doubt that marijuana is big business,” added Chris Walsh, CEO of MJBizDaily. “There is clear momentum for exponential growth, with New York and other states with dense populations starting legal sales.”

The ninth edition of Marijuana Business’ Factbook included these key findings:

100% of investors expect the industry to do better in 2021 than in 2020.
The cannabis industry will offer more than 400,000 full-time jobs in 2021.
An adult-use market in New York, the country’s financial hub, is expected to reach annual sales of $2.5 billion by year five.

But That’s Just Skimming This Mega Opportunity’s Surface

So you may be wondering – why is Quantum1 Cannabis / Quizam (CSE: QQ | OTCQB: QQQFFCSE: QQ | OTCQB: QQQFF) uniquely positioned to dominate this trend?

It takes a deep dive into the mechanics of the industry to understand what’s really fueling investor interest in Quantum1.

You see, Quantum1 Cannabis is on the retail side of the industry, currently operating six dispensaries in Western Canada.

From both the legal and financial aspects, operating dispensaries have had to pass stringent qualifications to even be considered for a license.

All of which Quantum1 achieved with flying colors, not just one time, but on six separate occasions.

It’s the reason the current environment favors established businesses that have already jumped through regulatory and financial hoops.  And it’s the key to companies like Quantum1 quickly gaining the upper edge as the opportunity to expand arises.

It Takes Deep Pockets To Play At This High Level

Cannabis is and always will be a cash business.

Once you start reading about the prohibitive costs of opening even a single dispensary, it makes a lot of sense why there are so many cannabis farmers in comparison.

You’ll also get a feeling for Quantum1 Cannabis’ tremendous success at opening six dispensaries in British Colombia.  A monumental feat when you consider that Trulieve Cannabis (OTC:TCNNF), has but one dispensary in California (mind you, California is currently the world’s largest legal cannabis market).

Application fees alone cost $252,000 with no promise of approval.

Then cannabis companies have to pay $9,000 in federal fees and $33,000 in local application fees per dispensary.11

Frankly, when you understand the business, those fees are a drop in the bucket.

Because, according to COVA, which makes software for cannabis dispensaries, that’s when the costs really start to add up.

  • There’s an average $100,000 in annual rent for each dispensary.
  • Plus $50,000 for interior renovations – much of it to meet federal regulations.
  • It costs an average of $50,000 to install high-tech security and surveillance systems.
  • Another $25,000 for the type of business equipment that can track sales and inventory in a way that regulators approve.
  • Then there’s $250,000 for staffing.
  • Finally, a dispensary will need about $150,000 in startup costs to buy its initial supply of cannabis.

As COVA noted, “When applying for your license and permits, you have to prove that you have enough capital to remain a viable company in the industry.

“Some states don’t require that you have any assets at all, but others like Pennsylvania stipulate that you have $2,000,000 in assets with at least $500,000 of it in liquid cash.”

And then everyone on the team has to pass a background check.

When you add it up, the monetary outlay cost Quantum1 Cannabis / Quizam (CSE: QQ | OTCQB: QQQFFCSE: QQ | OTCQB: QQQFF) many millions to open six dispensaries.

And as for Quantum1’s prospects in the U.S. – because of its solid Canadian foundation, its prospects could be bright… especially considering that as a proven operator it has growing revenues and positive gross profits.

While it could be on pace to generate as much as $30 million in revenue next year in Canada… it could see even greater success in the U.S. once nationwide legalization occurs.

Remember Quantum1 Cannabis is near heroic in its ability to clear the most onerous of regulatory barriers, making that prospect a very real possibility.

And it certainly helps that Quantum1 Cannabis / Quizam (CSE: QQ | OTCQB: QQQFFCSE: QQ | OTCQB: QQQFF) has already cleared the barrier of entry to be publicly traded on both U.S. and Canadian markets.

8 Reasons Why Quantum1 Cannabis / Quizam (CSE: QQ | OTCQB: QQQFFCSE: QQ | OTCQB: QQQFF) Could Be A Candidate For Sustained Success

  1. Jumping Through Hoops — Quantum1 has opened six dispensaries in Western Canada, where the paperwork and regulations are challenging.
  2. Cash On Hand – When all the fees are added up, it takes anywhere from $500,000 to $1 million to license and open a cannabis dispensary. Quantum1 is used to paying heavy fees.
  3. Growing Quickly – Quantum1 CEO, Russ Rossi, noted during a recent interview that year-on-year, his company’s Q3 revenue jumped by 591%.
  4. Let The Craziness Begin – The Senate’s desire for widescale cannabis legalization is about to set loose a stock market frenzy yet unseen in the cannabis investment community.
  5. Banking Bonanza – Legislation in both houses of Congress would finally allow financial institutions and banks to provide their services to cannabis – marijuana and hemp – clients without fear of federal sanctions. This is the final step needed before end the nationwide cannabis prohibition. The legislation enjoys bi-partisan support, and is in “position A” for passing in 2021.
  6. Secret Sauce – This is wild, the value of marijuana sales is about to grow to two times that of firearms and ammunition, and three times that of McDonald’s sales revenue in the U.S. That’s a mega trend.
  7. The Safe Play – Anyone who remembers the Wild West that broke out when Canada legalized recreational cannabis can use that as a starting point for what could happen in the U.S. Investors who don’t buy Quantum1 Cannabis should still use it as a measure against the torrent of small cannabis companies that could be about to overrun the U.S. stock markets.
  8. The Wild Card – There will be tons of new excitement in the U.S. cannabis industry. Cash will flow and mergers and acquisitions could happen at breakneck speed. It would not be too surprising to find a suitor paying $2 to $3 dollars a share for a company that knows the cannabis retail sector’s ropes.

This a rare moment in time for cannabis investors.

A whole new world is set to open up.

Experience will count.

Now would be a good time to line up for what could be mega-trend returns.

That means today’s share price could be the lowest price you will have the opportunity to buy Quantum1 Cannabis / Quizam (CSE: QQ | OTCQB: QQQFFCSE: QQ | OTCQB: QQQFF).

That could give you a chance to put yourself among its earliest and biggest winners.

But please, before you do take any action, make sure to show your investment advisor or broker a copy of this story.

When the legal cannabis dam breaks they’ll have to be on their toes because the action will be intense.

But, when you slow down and think about it, chances are you’ll both be in agreement that Quantum1 Cannabis / Quizam (CSE: QQ | OTCQB: QQQFFCSE: QQ | OTCQB: QQQFF) is a high-potential legal cannabis sector play.

[optin-monster slug="v2rb2tvllfjwfquvppyy"]

Learn More About Quantum1 Cannabis (CSE: QQ | OTCQB: QQQFFCSE: QQ | OTCQB: QQQFF) at your brokerage today!




IMPORTANT NOTICE AND DISCLAIMER This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Publisher has not been compensated by any of the profiled companies. The Publisher’s compensation for articles appearing on this website is as follows:

  • The Publisher has been paid approximately $500 per week while the advertisement campaign was active by Think Ink Media as compensation to host the article profiling Quantum1 Cannabis.
The Publisher has not participated in the creation of the content of any articles appearing on this website and so cannot guarantee the accuracy or completeness of the information in any of the articles. The Publisher expressly disclaims any responsibility or liability for statements made in any of the articles. SHARE OWNERSHIP. The Publisher does not own any shares of any profiled company and has no information concerning share ownership by others of any profiled company. The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. NO SECURITIES OFFERED. The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. INDEMNIFICATION/RELEASE OF LIABILITY. By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions. LINKS TO THIRD PARTY WEBSITES. This website enables users to link to external websites not under the control of The Publisher. The Publisher has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Publisher expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety. INTELLECTUAL PROPERTY. The Market Tactic is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders.  The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.